Glyxambi

Before taking this medicine

Do not take Glyxambi if you are allergic to empagliflozin, linagliptin or any other ingredient in the medicine. Serious allergic reactions have occurred, including anaphylaxis, swelling beneath the skin and severe peeling skin reactions. Glyxambi requires caution in people at risk of ketoacidosis, including those with type 1 diabetes. Ketoacidosis must be considered regardless of blood glucose levels. Stop Glyxambi if ketoacidosis or inflammation of the pancreas (pancreatitis) is suspected and seek urgent medical assessment. Kidney problems, older age and use of loop diuretics increase concerns about fluid loss and kidney function. Fluid levels and kidney function should be checked before treatment in these patients and monitored during treatment. Taking Glyxambi with insulin or medicines that stimulate insulin release can increase the risk of low blood sugar. Other warnings include serious urinary and genital infections, lower-limb infections or ulcers, severe joint pain, and a blistering skin condition called bullous pemphigoid. Report blisters or skin sores. Seek immediate assessment for pain, tenderness, redness or swelling around the genitals or the area between the genitals and anus, especially with fever or feeling unwell. People with risk factors for heart failure need careful assessment and monitoring. Heart failure has been observed with two other medicines in the same class as linagliptin. Glyxambi may pose a risk to an unborn baby, particularly during the second and third trimesters, and is not recommended during breastfeeding. Its safety and effectiveness in children have not been established.